drugset / Trial / NCT00716274

Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

NCT00716274

Phase 4 Completed 110 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia

Timeline

Start
2008-09
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1 mg/kg Oral
Subject Atomoxetine Other / unclassified 1.4 mg/kg Oral